Nadim Yared is a medtech CEO who is not afraid of digging into the details—the regulatory details; the nooks and crannies of Medicare coverage, coding, and payment; the finer-points of p-values and novel clinical trial designs. He has dug in deep on these matters and more during his 15 years at the helm of CVRx Inc., which as recently transitioned to a commercial phase, public company with its Barostim Neo heart failure device. And he has also done so as part of his very active role in cross-industry endeavors on the boards of AdvaMed, the Medical Device Innovation Consortium, and, most recently, the CRO NAMSA, where is currently the board chair. In this conversation, Yared talks about the evolution and what to look for next at FDA, CMS, and in the clinical research realm.
One update note: During the interview, Yared discusses the Medicare Coverage of Innovative Technology (MCIT) program at CMS. After the conversation took place, CMS issued a proposed rule to repeal MCIT before it takes effect in December and the agency stated plans to pursue new rulemaking. In a follow-up phone call with Market Pathways, Yared called this a “stunning reversal” from CMS.
View Market Pathways’ updated insights on MCIT and what’s to come at CMS: https://bit.ly/3i1SiEj
View our recent feature article on CVRx’s reimbursement strategy: https://bit.ly/3zCrhx8
View the latest issue of Market Pathways: https://bit.ly/2UEqmO9
About Market Pathways Your premium guide to global medical device regulation, reimbursement and policy. Market Pathways delivers incomparable intelligence exploring the people, challenges, and opportunities impacting the global medtech regulatory and reimbursement community. View the latest issue of Market Pathways on MyStrategist.com
